| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23454 | V0162 | A novel, high affinity and long-acting antagonist of human M3 muscarinic acetylcholine receptor with pKi of 9.03-9.21. |
|
| DC22756 | CHF6001 | A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM. |
|
| DC24013 | MUT-056399 | A novel, highly potent inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. |
|
| DC11676 | NS15370 Featured | A novel, highly potent positive modulator of Kv7 channels with EC50 of 100 nM (Kv7.2-Kv7.5). |
|
| DC21389 | NKTR-181 | A novel, long-acting and orally active, selective mu-opioid agonist that displays higher binding affinity (Ki=237 nM) at the MOR than kappa and delta opioid receptors (>100-fold). |
|
| DC12011 | KU-32 | A novel, novobiocin-based, C-terminal inhibitor of Hsp90 and a potent inducer of Hsp70. |
|
| DC24094 | Dofequidar | A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR. |
|
| DC22599 | GLPG-0492 | A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM. |
|
| DC21542 | PTC-596 | A novel, orally active, small molecule inhibitor of BMI-1 that accelerates BMI-1 degradation, inhibits AML cells growth with IC50 of <100 nM. |
|
| DC22981 | A-37 | A novel, potent and selective ALDH1A1 inhibitor with Ki of 300 nM and IC50 of 4.6 uM. |
|
| DC11799 | G1T38 | A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
|
| DC11800 | G1T38 dihydrochloride | A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
|
| DC21033 | Trilaciclib hydrochloride(G1T28) Featured | A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
|
| DC11804 | IQS-019 | A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
|
| DC11805 | IQS-019 mesylate | A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
|
| DC20680 | AS1604498 | A novel, potent nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with IC50 of 44 nM. |
|
| DC22533 | Eleclazine hydrochloride Featured | A novel, potent, and selective inhibitor of Late sodium current (late INa) for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia–ventricular fibrillation (VT–VF). |
|
| DC11938 | IPI-3063 | A novel, potent, and selective p110δ PI3K inhibitor with IC50 of 0.1 nM in cell-based assays. |
|
| DC26067 | BI1002494 trifluoroacetate | A novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with enzyme IC50 of 30 nM, cell IC50 of 7 nM (FcεR1-mediated histamine release in human monocyte-derived mast cells, in the presence of 0.1% albumin). |
|
| DC11778 | PKC-IN-6c | A novel, potent, brain permeant PKC inhibitor with IC50 of 80 nM, without detectable binding to the estrogen receptor (Ki>10 uM). |
|
| DC20439 | LXRβ agonist 17 Featured | LXRβ agonist 17 is a novel, potent, orally active liver X receptor β (LXRβ) agonist with Ki/EC50 of 3/21 nM, displays 27-fold selectivity over LXRα; also exhibits excellent selectivity against other nuclear hormone receptors (>3,000-fold); induces the expression of LXR target genes in vitro and in vivo. |
|
| DC22699 | JNJ-26070109 | A novel, potent, selective orally active CCK-2 receptor antagonist with pKi of 8.49 for hCCK2. |
|
| DC11970 | KU675 Featured | A novel, second-generation C-terminal Hsp90 inhibitor with Kd of 191 and 726 uM for Hsp90α and Hsp90β, respectively. |
|
| DC11853 | AC-73 | A novel, specific CD147 inhibitor that can specifically disrupt CD147 dimerization, inhibits the motility and invasion of HCC cells (IC50=7-10 uM). |
|
| DC22991 | IRES-C11 | A novel, spectfic c-Myc IRES (internal ribosome entry site) function inhibitor that prevents binding of hnRNP A1 to the Myc IRES and specifically inhibits Myc IRES activity in MM cells. |
|
| DC21050 | FN1-8 Featured | FN1-8 is a novel, synthetic small molecule that efficiently interferes with Gli/TAF9 interaction and downregulate Gli/TAF9-dependent transcriptional activity (at 15 uM); inhibits non-canonical Gli activation and acts downstream of the canonical Hh pathway; suppresses cancer cell proliferation in vitro and inhibits tumor growth in vivo. |
|
| DC10533 | PKM2 inhibitor(compound 3k) Featured | A novle PKM2 inhibitor inhibitor. |
|
| DC21284 | MK-0608 | A nucleoside analogue that shows potent inhibition for replication of several mosquito-borne flaviviruses including DENV and ZIKV. |
|
| DC23940 | NM107 Featured | NM-107, also known as 2'-C-Methylcytidine; 2'-C-MeC; 2-CMC; mCyd ; 2'CMeC; 2CMC, is a a potent and selective anti-viral drug. NM-107 showed activity to inhibit the replication of foot-and-mouth disease virus. NM-107 exerts potent anti-DENV activity in DENV subgenomic RNA replicon and infectious systems, with an IC50 value of 11.2±0.3μM. NM-107 may be a promising compound for the development of direct-acting antivirals against DENV infection. |
|
| DC22384 | Abacavir sulfate | A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.. |
|
